Is the early use of ketamine effective as an opioid sparing adjunct for treating pain in sickle cell disease patients?

Research
Written By Christine Briscoe

Authors: Vineetha Reddy Nallagatla and Natasha M Archer

Published: 28 April 2025

Read More
Christine Briscoe
Previous

Initial evaluation of an intervention to address provider implicit bias in pediatric sickle cell disease pain care: A mixed methods pilot study
Next

An Ethical Allocation Scheme for Scarce Gene Therapies in Sickle Cell Disease andTransfusion-Dependent β-Thalassemia